• 1. 国家卫生健康委医院管理研究所，医疗质量研究理论、方法及创新实践（编号：YLZLXZ23G113）, 202401-202412, 1 万元，主持，在研
• 
  
• 2. 国家自然科学青年基金，基于医疗大数据与机器学习的缺血性卒中院内复发风险预测模型研究 （编号：72004146），202101-202312，24万元，主持，在研
• 
  
• 3.北京市医院管理中心，基于医疗大数据与机器学习的缺血性卒中院内复发风险预测模型研究 （编号：PX2021024），202101-202312，15万元，主持，在研
• 
  
• 4.北京市医院管理中心，基于炎症标志物的急性轻型缺血性卒中早期神经功能恶化预测模型研究（编号：QML20210501），202201 -202312，6万元，主持，在研
• 
  
• 5.北京天坛医院青年基金，临床研究统计图表使用指南及软件程序包的开发（编号：2016-YQN-07），201701-201812，3万元，主持，结题

In English

1. Gu HQ, Wang CJ, Yang X, et al. Clinical characteristics, in-hospitalmanagement, and outcomes of patients with in-hospital vs. community-onsetischaemic stroke: a hospital-based cohort study. The Lancet Regional Health- Western Pacific. 2023;38:100890. doi: 10/gsnz6w

2. Wang CJ, Gu HQ, ZhangXM, et al. Temporal trends and rural–urban disparities in cerebrovascularrisk factors, in-hospital management and outcomes in ischaemic strokes in Chinafrom 2005 to 2015: a nationwide serial cross-sectional survey. Stroke VascNeurol. 2023;8(1):34-50. doi:10.1136/svn-2022-001552

3.  Gu H-Q, Wang C-J, Zhang X-M,Jiang Y, Li H, Meng X, Yang X, Liu L-P, Zhao X-Q, Wang Y-L, etal. Ten-year trends in sex differences in cardiovascular risk factors,in-hospital management, and outcomes of ischemic stroke in China: Analyses of anationwide serial cross-sectional survey from 2005 to 2015. Int J Stroke.2023;18:821–828. doi: 10.1177/17474930231158226

4. Wang CJ, Gu HQ, Zong LX,et al. Effectiveness of a Quality Improvement Intervention on ReperfusionTreatment for Patients With Acute Ischemic Stroke: A Stepped-Wedge ClusterRandomized Clinical Trial. JAMA Netw Open. 2023;6(6):e2316465. doi:10.1001/jamanetworkopen.2023.16465

5.  Chen ZM, Gu HQ, Mo JL,et al. U-shaped association between low-density lipoprotein cholesterollevels and risk of all-cause mortality mediated by post-stroke infection inacute ischemic stroke. Sci Bull. Published online May 2023. doi:10/gr95f6

6. Gu HQ, Yang X, Li J, et al. Mediation effect of stroke recurrence inthe association between post‐stroke interleukin‐6 and functional disability. CNSNeurosci Ther. Published online 2023. doi: 10.1111/cns.14289

7.  Gu HQ. Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events inPatients With Atrial Fibrillation. Jama-J Am Med Assoc. 2022; 327 (13):1290. Doi: 10.1001/jama.2022.1425

8.  Gu HQ, Wang CJ, Yang X, et al. Sex differences in vascular riskfactors, in-hospital management, and outcomes of patients with acute ischemicstroke in China. Eur J Neurol. 2022; 29 (1): 188-198. Doi: 10.1111/ene.15124

9. Gu HQ, Yang KX, Lin JX, et al. Association between high-sensitivityC-reactive protein, functional disability, and stroke recurrence in patientswith acute ischaemic stroke: A mediation analysis. eBiomedicine.2022;80:104054. Doi: 10.1016/j.ebiom.2022.104054

10. Liu C, Gu HQ, Yang X, etal. Pre-stroke dementia and in-hospital outcomes in the Chinese StrokeCenter Alliance. Ann Transl Med. 2022; 10 (19): 1050. Doi: 10.21037/atm-22-723

11. Wang HY, Gu HQ, Zhou Q,et al. Thrombolysis, time-to-treatment and in-hospital outcomes amongyoung adults with ischaemic stroke in China: findings from a nationwideregistry study in China. BMJ Open. 2022; 12 (6): e 055055. Doi: 10.1136/bmjopen-2021-055055

12. Wang YJ, Li ZX, Gu HQ,et al. China Stroke Statistics: an update on the 2019 report from the NationalCenter for Healthcare Quality Management in Neurological Diseases, ChinaNational Clinical Research Center for Neurological Diseases, the Chinese StrokeAssociation, National Center for Chronic and Non-communicable Disease Controland Prevention, Chinese Center for Disease Control and Prevention and Institutefor Global Neuroscience and Stroke Collaborations. Stroke Vasc Neurol.2022; 7 (5): 415-450. Doi: 10.1136/svn-2021-001374

13. Weng JX, Gu HQ, Wang S,et al. External validation of ABCD series scores for predicting earlystroke events following transient ischemic attack in a large nationwideregistry. Eur Stroke J. 2022; 7 (4): 439-446. Doi: 10.1177/23969873221113145

14. Chen B, Gu HQ, Liu Y, etal. A model to predict the risk of mortality in severely ill COVID-19patients. Comput Struct Biotec. 2021;19:1694-1700. Doi: 10.1016/j.csbj.2021.03.012

15. Chen B, Lu C, Gu HQ, etal. Serum Uric Acid Concentrations and Risk of Adverse Outcomes inPatients With COVID-19. Front Endocrinol. 2021;12:633767. Doi: 10.3389/fendo.2021.633767

16. Gu HQ, Wang J. Prediction Models for COVID-19 Need Further Improvements. JAMAIntern Med. 2021; 181 (1): 143-144. Doi: 10.1001/jamainternmed.2020.5740

17.  Gu HQ, Yang KX, Yang X, et al. Guideline-directed low-densitylipoprotein management in high-risk ischemic stroke or transient ischemicattack admissions in China from 2015 to 2019. Ann Transl Med. 2021; 9(15): 1224. Doi: 10.21037/atm-21-1467

18. Gu HQ, Yang X, Wang CJ, et al. Assessment of Trends inGuideline-Based Oral Anticoagulant Prescription for Patients With IschemicStroke and Atrial Fibrillation in China. JAMA Netw Open. 2021; 4 (7): e2118816. Doi: 10.1001/jamanetworkopen.2021.18816

19. Gu HQ, Yang X, Wang CJ, et al. Clinical Characteristics, Management,and In-Hospital Outcomes in Patients With Stroke or Transient Ischemic Attackin China. JAMA Netw Open. 2021; 4 (8): e 2120745. Doi: 10.1001/jamanetworkopen.2021.20745

20.  Huang ZX, Gu HQ, Yang X,Wang CJ, Wang YJ, Li ZX. Risk factors for in-hospital mortality among acuteischemic stroke patients in China: a nationwide prospective study. NeurolRes. 2021; 43 (5): 387-395. Doi: 10.1080/01616412.2020.1866356

21.  Li ZX, Xiong Y, Gu HQ,et al. P 2 Y 12 Inhibitors Plus Aspirin Versus Aspirin Alone in PatientsWith Minor Stroke or High-Risk Transient Ischemic Attack. Stroke. 2021;52 (7): 2250-2257. Doi: 10.1161/STROKEAHA.120.033040

22.  Wang RR, Gu HQ, Wei YY,et al. Development and Validation of a Prognostic Model for One-yearSurvival of Cirrhosis Patients with First-ever Spontaneous BacterialPeritonitis. J Clin Transl Hepato. 2021; 9 (5): 647-654. Doi: 10.14218/JCTH.2021.00031

23.  Xiu Y, Gu H, Li X, etal. Incidence and Mortality of Acute Disseminated Encephalomyelitis inChina: A Nationwide Population-Based Study. Neurosci Bull. 2021; 37 (6):804-808. Doi: 10.1007/s12264-021-00642-740.

24. Gu HQ, Liu C. Clinical prediction models: evaluation matters. AnnTransl Med. 2020; 8 (4): 72. Doi: 10.21037/atm.2019.11.143

25.  Gu HQ, Xie XW, Jing J, et al. Shuxuetong for Prevention ofrecurrence in Acute Cerebrovascular events with Embolism (SPACE) trial:rationale and design. Stroke Vasc Neurol. 2020; 5 (3): 311-314. Doi: 10.1136/svn-2019-000293

26.  Wang YJ, Li ZX, Gu HQ,et al. China Stroke Statistics 2019: A Report From the National Center forHealthcare Quality Management in Neurological Diseases, China National ClinicalResearch Center for Neurological Diseases, the Chinese Stroke Association,National Center for Chronic and Non-communicable Disease Control andPrevention, Chinese Center for Disease Control and Prevention and Institute forGlobal Neuroscience and Stroke Collaborations. Stroke Vasc Neurol. 2020;5 (3): 211-239. Doi: 10.1136/svn-2020-000457

27. Gu HQ, Liu LP. Letter by Gu and Liu Regarding Article, “HbA 1 c (GlycatedHemoglobin) Levels and Clinical Outcome Post-Mechanical Thrombectomy inPatients With Large Vessel Occlusion.” Stroke. 2019; 50 (6): e 171. Doi:10.1161/STROKEAHA.119.025575

28. Gu HQ, Rao ZZ, Yang X, et al. Use of Emergency Medical Services andTimely Treatment Among Ischemic Stroke. Stroke. 2019; 50 (4): 1013-1016.Doi: 10.1161/STROKEAHA.118.024232

29. Gu HQ, Yang X, Rao ZZ, et al. Disparities in outcomes associatedwith rural-urban insurance status in China among inpatient women with stroke: aregistry-based cohort study. Ann Transl Med. 2019; 7 (18): 426. Doi: 10.21037/atm.2019.08.125

30. Xie X, Gu HQ, Wang X, etal. Assessing the applicability of 2017 ACC/AHA hypertension guidelinesfor secondary stroke prevention in the BOSS study. J Clin Hypertens.2019; 21 (10): 1534-1541. Doi: 10.1111/jch.13653

31.  Yan R, Gu HQ, Wang W, MaL, Li W, Group CR. Health-related quality of life in blood pressure control andblood lipid-lowering therapies: results from the CHIEF randomized controlledtrial. Hypertens Res. 2019; 42 (10): 1561-1571. Doi: 10.1038/s41440-019-0281-z

32. Yang XM, Rao ZZ, Gu HQ,et al. Atrial Fibrillation Known Before or Detected After Stroke ShareSimilar Risk of Ischemic Stroke Recurrence and Death. Stroke. 2019; 50(5): 1124-1129. Doi: 10.1161/STROKEAHA.118.024176

33.  Gu HQ, Li DJ, Liu C, Rao ZZ. %ggBaseline: a SAS macro for analyzing andreporting baseline characteristics automatically in medical research. AnnTransl Med. 2018; 6 (16): 326. Doi: 10.21037/atm.2018.08.13

34. Gu HQ, Li ZX, Zhao XQ, et al. Insurance status and 1-year outcomesof stroke and transient ischaemic attack: a registry-based cohort study inChina. Bmj Open. 2018; 8 (7): e021334. Doi: 10.1136/bmjopen-2017-021334

35. Gu H, Hua K, Li W, Wang Y, Yang J. Safety and efficacy ofeverolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis ofrandomized controlled clinical trials and observational studies. Internationaljournal of cardiology. 2015;201:552-560. doi: 10.1016/j.ijcard.2015.02.097

36. Gu H, Li W, Yang J, Wang Y, Bo J, Liu L. Hypertension prevalence,awareness, treatment and control among Han and four ethnic minorities (Uygur,Hui, Mongolian and Dai) in China. Journal of human hypertension.2015;29(9): 555-560. doi: 10.1038/jhh.2014.123

In Chinese

1.  Jin A,Qin Z, Shang H, Gu H.N-of-1 Trial. Chin J Stroke. 2023;18(03): 367-371.

2.  Wang M, Wang C, Li Z, Gu H.Stepped Wedge Cluster Randomized Trials. Chin J Stroke. 2023; 18 (01):114-122.

3. Zhou Q, Yang K, Jiang Y, GuH. Registry-Based Randomized Clinical Trials. Chin J Stroke. 2022;17 (10): 1145-1151.

4. Yang K, Zhou Q, Jiang Y, GuH. Adaptive Design Randomized Controlled Clinical Trials. Chin J Stroke.2022; 17 (10): 1152-1158.

5.  Gu HQ, Yang X, Wang CJ, et al. Incidence, Risk Factors andIn-hospital Outcomes of Symptomatic Seizures after Subarachnoid Hemorrhage:Analysis from China Stroke Center Alliance Registry Database. Chin J Stroke.2020, 15 (06): 620-625.

6.  Gu HQ, Wang CJ, Li ZX, et al. Comparison of Prediction Models forIn-hospital Stroke Recurrence in Patients with Ischemic Stroke Based onLogistic Regression and XGBoost Methods. Chin J Stroke. 2020, 15 (06):587-594.

7. Gu HQ, Wang JF, Zhang ZH, et al. Clinical Prediction Models: BasicConcepts, Application Scenarios, and Research Strategies. Chin J Evid BasedCardiovasc Med. 2018, 10 (12): 1454-62.

8. Gu HQ, Wang JF, Zhang ZH, et al. Clinical Prediction Models: ModelDevelopment. Chin J Evid Based Cardiovasc Med. 2019, 11 (1): 9-12.

9.  Wang JF, Zhang ZH, Zhou ZR,GuHQ. Clinical Prediction Models: Model Validation. Chin J Evid BasedCardiovasc Med. 2019, 11 (2): 145-8.

10. Gu HQ. A brief introduction of statistical analysis strategy and statisticalcharts for clinical research. Chin J Evid Based Cardiovasc Med. 2018, 10(7): 785-8.

11. Gu H. Statistical methods and statistical charts for baselineinformation in clinical research. Chin J Evid Based Cardiovasc Med.2018, 10 (8): 910-2.

12. Gu H. Statistical methods and statistical charts for effect estimationin clinical research. Chin J Evid Based Cardiovasc Med. 2018, 10 (9):1048-52.

13. Gu H. Statistical strategy and statistical charts for sensitivityanalyses in clinical research. Chin J Evid Based Cardiovasc Med. 2018,10 (10): 1171-5.

14.  Gu H. Statistical strategy and statistical charts for risk factorsanalysis in clinical research. Chin J Evid Based Cardiovasc Med. 2018,10 (11): 1292-4.

15. Gu H, Li W, Wang Y. Standardization and adjustment of Rate inepidemiology study: methodology and SAS macro code. Chin J Dis Control Prev.2014,18 : 557-60.

16. Gu H, Wang Y, Li W. Progress on methodology of adjusting survivalcurves. Chin J Epidemiol. 2014;35:97-9.

17. Gu H, Wang Y, Li W. Application of the Cochrane Collaboration’s tool forassessing risk of bias in meta-analysis of randomized controlled trails. ChineseCirculation Journal. 2014;29:147-9.

18. Gu H, Li W. How to understand the adjustment of “Rate” in epidemiologystudies. Chinese Circulation Journal. 2013;28:155.

19. Gu H, Pang L, Liu E, Yin W, Luo W, Wang C, Cao X, Rou K and Wu Z.Effectivness of integrated and intensified intervention on increasing methadonedose among clients of methadone maintenance treatment (MMT) in China. Chin JAIDS & STD. 2011;17:636-9.

1. 谷鸿秋. SAS 编程演义. 北京: 清华大学出版社; 2017.

2. 谷鸿秋 等. The Little SAS Book 中文版. 北京: 清华大学出版社; 2018.